| Literature DB >> 24480825 |
Björn Tampe1, Desiree Tampe1, Claudia A Müller2, Hikaru Sugimoto3, Valerie LeBleu3, Xingbo Xu4, Gerhard A Müller1, Elisabeth M Zeisberg4, Raghu Kalluri5, Michael Zeisberg6.
Abstract
Methylation of CpG island promoters is an epigenetic event that can effectively silence transcription over multiple cell generations. Hypermethylation of the Rasal1 promoter contributes to activation of fibroblasts and progression of kidney fibrosis. Here, we explored whether such causative hypermethylation could be reversed through endogenous mechanisms and whether such reversal of hypermethylation is a constituent of the antifibrotic activity of bone morphogenic protein 7 (BMP7). We show that successful inhibition of experimental kidney fibrosis through administration of BMP7 associates with normalization of Rasal1 promoter hypermethylation. Furthermore, this reversal of pathologic hypermethylation was achieved specifically through Tet3-mediated hydroxymethylation. Collectively, our findings reveal a new mechanism that may be exploited to facilitate therapeutic DNA demethylation to reverse kidney fibrosis.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24480825 PMCID: PMC4005308 DOI: 10.1681/ASN.2013070723
Source DB: PubMed Journal: J Am Soc Nephrol ISSN: 1046-6673 Impact factor: 10.121